Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (291-300 of 344) with videos related to

Pageof 35
Sort By:
Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerNick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Biomedical Reports|October 1, 2019
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencingSatoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 2, 2024
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancerAmane Jubashi, Izuma Nakayama, Shigehiro Koganemaru, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Nature Medicine|July 31, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A Shah, Kohei Shitara, Jaffer A Ajani, et al.
Pageof 35

Showing results (291-300 of 344) with videos related to

Sort By:
Pageof 35
Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerNick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Biomedical Reports|October 1, 2019
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencingSatoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 2, 2024
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancerAmane Jubashi, Izuma Nakayama, Shigehiro Koganemaru, et al.
Nature Medicine|March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trialKohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Nature Medicine|July 31, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A Shah, Kohei Shitara, Jaffer A Ajani, et al.
Pageof 35